FDA says Nara Company's seafood HACCP plan is inadequate and makes fish fillets adulterated.
What happened
FDA conducted a Foreign Regulatory Assessment of Nara Company Ltd.'s seafood processing facility in Japan on September 7, 2022, and issued an FDA 483 listing observations. FDA found serious violations of the seafood HACCP regulation, including missing food safety hazards and inadequate critical limits. The company responded on October 7, 2022, with a revised HACCP plan dated September 19, 2022, but FDA found the response inadequate.
What FDA found
The revised HACCP plan did not list pathogenic bacteria growth and toxin formation or metal inclusion as food safety hazards.
21 CFR 123.6(a) and (c)(1)The critical limits for unapproved aquaculture drugs were inadequate because oxytetracycline is not approved for buri (Seriola quinqueradiata).
21 CFR 123.3(c)(3)The critical limits for scombrotoxin (histamine) formation were inadequate and lacked harvest vessel records or histamine testing, sensory examination, internal temperature measurements, and transit control.
21 CFR 123.3(c)(3)The critical limits for Clostridium botulinum and undeclared allergens were inadequate, including no critical limit to ensure labels are properly applied to each finished package.
21 CFR 123.3(c)(3)
What FDA wants
FDA tells the company to respond in writing within 15 working days of receipt, outline specific corrections, and include a revised HACCP plan plus 5 consecutive days of completed monitoring records for 5 production date codes; if corrections cannot be completed, the company must explain the delay and state when it will correct remaining violations.
Who should pay attention
- US importers and distributors of frozen seafood
- brands buying finished fish products from this processor
- retailers and foodservice buyers sourcing aquaculture fish
This is a summary. Read the original letter on fda.gov.